Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2021

Dinalankara W, Ke Q, Geman D, Marchionni L. An R package for divergence analysis of omics data. PLoS One. 2021;16(4):e0249002.

Miller DL, Ribeiro EA, Roy-Chowdhuri S, Illei PB, Siddiqui MT, Ali SZ. Renal medullary carcinoma involving serous cavity fluids: a cytomorphologic study of 12 cases. J Am Soc Cytopathol. 2021;10(2):187-196.

Khan KM, Kothari P, Du B, Dannenberg AJ, Falcone DJ. Correction: Matrix Metalloproteinase-Dependent Microsomal Prostaglandin E Synthase-1 Expression in Macrophages: Role of TNF-α and the EP4 Prostanoid Receptor. J Immunol. 2021;207(2):746-747.

Abuhelaiqa E, Snopkowski C, Li C, Salvatore S, Lee JR, Muthukumar T, et al. Validation of a noninvasive prognostic signature for allograft failure following BK virus associated nephropathy. Clin Transplant. 2021;35(2):e14200.

Armstrong AJ, Li X, Tucker M, Li S, Mu XJ, Eng KW, et al. Molecular medicine tumor board: whole-genome sequencing to inform on personalized medicine for a man with advanced prostate cancer. Prostate Cancer Prostatic Dis. 2021;24(3):786-793.

Wang X, Gkrouzman E, Andrade DC, Andreoli L, Barbhaiya M, H Belmont M, et al. COVID-19 and antiphospholipid antibodies: A position statement and management guidance from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION). Lupus. 2021;30(14):2276-2285.

Park J, Foox J, Hether T, Danko D, Warren S, Kim Y, et al. Systemic Tissue and Cellular Disruption from SARS-CoV-2 Infection revealed in COVID-19 Autopsies and Spatial Omics Tissue Maps. bioRxiv. 2021.

Adib E, Nassar AH, Akl EW, Alaiwi SA, Nuzzo PV, Mouhieddine TH, et al. CDKN2A Alterations and Response to Immunotherapy in Solid Tumors. Clin Cancer Res. 2021;27(14):4025-4035.

Lopez A, Patel S, Geyer JT, Racchumi J, Chadburn A, Simonson P, et al. Comparison of Multiple Clinical Testing Modalities for Assessment of NPM1-Mutant AML. Front Oncol. 2021;11:701318.

Pappa T, Ahmadi S, Marqusee E, Johnson HL, Nehs MA, Cho NL, et al. Oncogenic Mutations in PI3K/AKT/mTOR Pathway Effectors Associate with Worse Prognosis in BRAFV600E -Driven Papillary Thyroid Cancer Patients. Clin Cancer Res. 2021;27(15):4256-4264.